论文部分内容阅读
目的观察小剂量尿激酶治疗发病1周以内的脑梗塞治疗效果,评价小剂量尿激酶的安全性。方法采用小剂量尿激酶连续静脉滴注5～7d,所有的病例均在脱水、活血化淤和抗凝治疗的基础上进行。结果发现治疗组神经功能缺损恢复程度明显高于对照组,住院日明显缩短,无一例出血。结论小剂量尿激酶连续静脉滴注治疗脑梗塞安全有效,可在临床进一步推广应用,但还需要设计良好的疗程和大规模的中心随机对照试验做进一步证实。
Objective To observe the therapeutic effect of cerebral infarction within 1 week after the onset of low-dose urokinase therapy and to evaluate the safety of low-dose urokinase. Methods Continuous low-dose urokinase intravenous infusion of 5 ~ 7d, all cases were in dehydration, promoting blood circulation and anticoagulant therapy based on. The results showed that the recovery of neurological deficit in the treatment group was significantly higher than that in the control group, the hospitalization days were significantly shorter, and no case of bleeding. Conclusions Continuous intravenous drip of low-dose urokinase for the treatment of cerebral infarction is safe and effective and can be further popularized in clinic. However, a well-designed course and a large-scale randomized controlled trial are needed to confirm.